|
CAH
Steroid Study
Riley Hospital for Children
Indianapolis, IN
Everyone who has CAH is treated with a type of medication known as a “glucocorticoid.”
There are several different glucocorticoids available, including hydrocortisone
(Cortef), prednisone and dexamethasone. Traditionally, many physicians treat
children with CAH with hydrocortisone, which is a short-acting glucocorticoid
that is usually given three times a day. Longer-acting glucocorticoids, such as
prednisone or dexamethasone, are not as commonly used because of potential
concerns related to growth. Little is known about the effects on growth, the
pituitary gland, or CAH control of these different types of glucocorticoids.
Improved understanding of the effects of hydrocortisone, prednisone, and
dexamethasone in children with CAH would lead to better treatment options,
including the potential of more simplified therapy with only once or twice daily
dosing.
Our goal is to compare
different glucocorticoids in children with CAH in order to optimize growth and
control of CAH so as to avoid the consequences of over-treatment and
under-treatment.
We are recruiting
children who have classic CAH, are not yet in puberty, and are between the ages
of 5 and 12 years old. Children will be enrolled at the General Clinical
Research Center (GCRC) at Indiana University School of Medicine affiliated with
Riley Hospital for Children in Indianapolis, IN. The study lasts for 18 weeks,
but requires only 4 visits to Indianapolis. Three of these visits will consist
of an overnight stay. Each participant will randomly be on a 6-week course of
each glucocorticoid (hydrocortisone, prednisone, or dexamethasone).
All overnight stays,
including labs, medications, and participation compensation, will be paid for by
the study. If one is traveling a long distance, arrangements can be made to
spend the night at the GCRC the night prior to an overnight stay at no cost.
If you are interested in
learning more about our study, please contact either Dr. Erica Eugster at (317)
274-3889, or Dr. Todd Nebesio at (317) 274- 3889 or by e-mail (tdnebesi@iupui.edu). |
CAH
Volunteers Needed
for Natural History Study
Principal Investigator: Dr. Deborah Merke, M.D.,
Pediatric Endocrinologist and Chief of Pediatric
Services at the National Institutes of Health Clinical
Center, Bethesda, Maryland
We are currently recruiting patients of all ages with CAH (both classic and
nonclassic) for a natural history study at the National Institutes of Health
(NIH) in Bethesda, Maryland. By studying the natural history of CAH in a large
population of patients, we hope to define new aspects of the disease. This will
allow us to develop new management and treatment approaches. Participants will
be seen as outpatients at the NIH Clinical Center in Bethesda, Maryland and may
be seen once, twice, or for ongoing care. Patients seen for a limited number of
visits will have a full report sent to their private physician. All testing is
free of charge and will include:
-
Genotyping (patients
with 21- Hydroxylase deficiency only)
-
Hormonal evaluation
including evaluation for insulin resistance
-
Psychological and
cognitive testing
-
Bone age (growing
children) and ultrasound
For more information
or to volunteer, please contact Carol VanRyzin at the NIH at (301) 451-0399. |
|
The studies advertised
on this page are new, as
provided to us by the researchers. Other studies
(previously advertised) are also available and can be
viewed on the CARES Foundation website.
The studies listed on the website include topics such
as (but not limited to): Women’s Hormones, Prenatal
Diagnosis, Children with CAH, Reproduction in Males
with CAH, and NCAH .
For more information, please visit
http://caresfoundation.org/clinical_trials.html.
|
